Journal of Community Genetics

, Volume 5, Issue 1, pp 13–29

Attitudes of health care professionals toward carrier screening for cystic fibrosis. A review of the literature

Review

Abstract

Recent technological developments in molecular genetics facilitate the large-scale detection of inherited genetic disorders and allow an increasing number of genetic conditions to be screened for (American College of Medical Genetics 2012). This technological evolution creates the background which makes reflection necessary about the desirability to offer community-based (preconception) carrier screening in the healthcare system. A positive attitude of potential providers is vital to the success of a screening program. Therefore, the objective of this article is to elaborate a review of the attitudes of healthcare professionals toward carrier screening. Examination of existing carrier screening programs could provide such information. The literature review will be focused on the attitudes toward carrier screening for cystic fibrosis (CF). The databases Pubmed and Web of Science, as well as the interface Google Scholar, were searched using the keywords for the period 1990–2011. Studies were selected if they were published in a peer-reviewed journal in English and described the attitudes of potential providers toward carrier screening. Eleven studies were retrieved describing the attitudes toward carrier screening for CF. In total, seven studies reported attitudes toward the best time for carrier screening; four studies described opinions toward the best setting to offer CF carrier screening; six studies investigated the willingness to be involved in a carrier screening program, and in total 11 articles reported the concerns about offering carrier screening. Ten papers described a general attitude toward carrier screening. We can conclude that health care providers state willingness to be involved in a carrier screening program, but there is need for appropriate education as well as adequate support given the time constraints already present in consultation. The prospect of an increasing number of genetic disorders for which screening becomes possible, and the potential increasing demand for such screening in the future calls for the need for further debate on the desirability of carrier screening and relevant questions such as the conditions screened, the providers involved, the information provision, and counseling.

Keywords

Carrier Screening Genetic Testing Attitude 

References

  1. ACMG The American College of Medical Genetics (2012) Points to Consider in the Clinical Application of Genomic Sequencing. Policy Statement. Available at: http://www.acmg.net/AM/Template.cfm?Section=Policy_Statements&Template=/CM/HTMLDisplay.cfm&ContentID=6979
  2. ACOG The American College of Obstetricians an Gynecologists (2005) Update on carrier screening for cystic fibrosis. Committee Opinion No. 325. Obstet Gynecol 106:1465–1468CrossRefGoogle Scholar
  3. ACOG The American College of Obstetricians an Gynecologists (2011) Update on carrier screening for cystic fibrosis. Committee Opinion No. 486. Obstet Gynecol 117:1028–1031CrossRefGoogle Scholar
  4. Andermann A, Blancquaert I, Beauchamp S, Dery V (2008) Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40years. Bull World Health Organ 86:317–9PubMedCentralPubMedCrossRefGoogle Scholar
  5. Angastiniotis M, Kyriakidou S, Hadjiminas M (1988) The Cyprus thalassemia control program. Birth Defects Orig Artic Ser 23:417–32PubMedGoogle Scholar
  6. Angastiniotis MA, Hadjiminas MG (1981) Prevention of thalassaemia in Cyprus. Lancet 1:369–71PubMedCrossRefGoogle Scholar
  7. Axworthy D, Brock DJ, Bobrow M, Marteau TM (1996) Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up. UK cystic fibrosis follow-up study group. Lancet 347:1443–6PubMedCrossRefGoogle Scholar
  8. Baars MJ, Henneman L, ten Kate LP (2004) Preconceptional cystic fibrosis carrier screening: opinions of general practitioners, gynecologists, and pediatricians in The Netherlands. Genet Test 8:431–6PubMedCrossRefGoogle Scholar
  9. Barlow-Stewart K, Burnett L, Proos A, Howell V, Huq F, Lazarus R, Aizenberg H (2003) A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. J Med Genet 40:e45PubMedCrossRefGoogle Scholar
  10. Bekker H, Denniss G, Modell M, Bobrow M, Marteau T (1994) The impact of population based screening for carriers of cystic fibrosis. J Med Genet 31:364–8PubMedCrossRefGoogle Scholar
  11. Bekker H, Modell M, Denniss G, Silver A, Mathew C, Bobrow M, Marteau T (1993) Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ 306:1584–6PubMedCrossRefGoogle Scholar
  12. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF (2011) Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 3:69–82CrossRefGoogle Scholar
  13. Borry P, Henneman L, Lakeman P, ten Kate LP, Cornel MC, Howard HC (2011) Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod 26:972–7PubMedCrossRefGoogle Scholar
  14. Boulton M, Cummings C, Williamson R (1996) The views of general practitioners on community carrier screening for cystic fibrosis. Br J Gen Pract 46:299–301PubMedCentralPubMedGoogle Scholar
  15. Boulton M, Williamson R (1995) General practice and new genetics: what do general practitioners know about community carrier screening for cystic fibrosis? Public Understand Sci 4:255–267CrossRefGoogle Scholar
  16. Bruni T, Mameli M, Pravettoni G, Boniolo G (2012) Cystic fibrosis carrier screening in Veneto (Italy): an ethical analysis. Med Health Care Philos 15:321–8PubMedCrossRefGoogle Scholar
  17. Castellani C, Macek M Jr, Cassiman JJ, Duff A, Massie J, ten Kate LP, Barton D, Cutting G, Dallapiccola B, Dequeker E, Girodon E, Grody W, Highsmith EW, Kaariainen H, Kruip S, Morris M, Pignatti PF, Pypops U, Schwarz M, Soller M, Stuhrman M, Cuppens H (2010) Benchmarks for cystic fibrosis carrier screening: a European consensus document. J Cyst Fibros 9:165–78PubMedCrossRefGoogle Scholar
  18. Childs B, Gordis L, Kaback MM, Kazazian HH Jr (1976) Tay-Sachs screening: social and psychological impact. Am J Hum Genet 28:550–8PubMedCentralPubMedGoogle Scholar
  19. Darcy D, Tian L, Taylor J, Schrijver I (2011) Cystic fibrosis carrier screening in obstetric clinical practice: knowledge, practices, and barriers, a decade after publication of screening guidelines. Genet Test Mol Biomarkers 15:517–23PubMedCrossRefGoogle Scholar
  20. Delatycki MB (2008) Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res Hum Genet 11:422–30PubMedCrossRefGoogle Scholar
  21. Denayer L, Welkenhuysen M, Evers-Kiebooms G, Cassiman JJ, Van den Berghe H (1996) The CF carrier status is not associated with a diminished self-concept or increased anxiety: results of psychometric testing after at least 1year. Clin Genet 49:232–6PubMedCrossRefGoogle Scholar
  22. Faden RR, Tambor ES, Chase GA, Geller G, Hofman KJ, Holtzman NA (1994) Attitudes of physicians and genetics professionals toward cystic fibrosis carrier screening. Am J Med Genet 50:1–11PubMedCrossRefGoogle Scholar
  23. Frumkin A, Zlotogora J (2008) Genetic screening for reproductive purposes at school: is it a good strategy? Am J Med Genet A 146A:264–9PubMedCrossRefGoogle Scholar
  24. Gason AA, Metcalfe SA, Delatycki MB, Petrou V, Sheffield E, Bankier A, Aitken M (2005) Tay Sachs disease carrier screening in schools: educational alternatives and cheekbrush sampling. Genet Med 7:626–32PubMedCrossRefGoogle Scholar
  25. Gilani AI, Jadoon AS, Qaiser R, Nasim S, Meraj R, Nasir N, Naqvi FF, Latif Z, Memon MA, Menezes EV, Malik I, Memon MZ, Kazim SF, Ahmad U (2007) Attitudes towards genetic diagnosis in Pakistan: a survey of medical and legal communities and parents of thalassemic children. Community Genet 10:140–6PubMedCrossRefGoogle Scholar
  26. Giordano PC, Plancke A, Van Meir CA, Janssen CA, Kok PJ, Van Rooijen-Nijdam IH, Tanis BC, van Huisseling JC, Versteegh FG (2006) Carrier diagnostics and prevention of hemoglobinopathies in early pregnancy in The Netherlands: a pilot study. Prenat Diagn 26:719–24PubMedCrossRefGoogle Scholar
  27. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ, Subcommittee on Cystic Fibrosis Screening AoGSCAACoMG (2001) Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 3:149–154PubMedCrossRefGoogle Scholar
  28. Hartley NE, Scotcher D, Harris H, Williamson P, Wallace A, Craufurd D, Harris R (1997) The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 34:459–64PubMedCrossRefGoogle Scholar
  29. Henneman L, Bramsen I, van der Ploeg HM, Ader HJ, van der Horst HE, Gille JJ, ten Kate LP (2001) Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet 38:695–703PubMedCrossRefGoogle Scholar
  30. Henneman L, Bramsen I, van Kempen L, van Acker MB, Pals G, van der Horst HE, Ader HJ, van der Ploeg HM, ten Kate LP (2003) Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. Community Genet 6:5–13PubMedCrossRefGoogle Scholar
  31. Henneman L, Poppelaars FA, ten Kate LP (2002) Evaluation of cystic fibrosis carrier screening programs according to genetic screening criteria. Genet Med 4:241–9PubMedCrossRefGoogle Scholar
  32. Hock KT, Christensen KD, Yashar BM, Roberts JS, Gollust SE, Uhlmann WR (2011) Direct-to-consumer genetic testing: an assessment of genetic counselors' knowledge and beliefs. Genet Med 13:325–32PubMedCentralPubMedCrossRefGoogle Scholar
  33. Howard HBP (2008) Direct-to-consumer genetic testing: more questions than benefits? Personalised Medicine 5:317–20CrossRefGoogle Scholar
  34. Howard HC, Borry P (2012) To ban or not to ban? Clinical geneticists' views on the regulation of direct-to-consumer genetic testing. EMBO Rep 13:791–4PubMedCentralPubMedCrossRefGoogle Scholar
  35. Human Genetics Commission (2011) Increasing options, informing choice: A report on preconception genetic testing and screening. Available at: http://www.hgc.gov.uk/Client/document.asp?DocId=315
  36. Ioannou L, Massie J, Lewis S, Petrou V, Gason A, Metcalfe S, Aitken MA, Bankier A, Delatycki MB (2010) Evaluation of a multi-disease carrier screening programme in Ashkenazi Jewish high schools. Clin Genet 78:21–31PubMedCrossRefGoogle Scholar
  37. Jackson L, Pyeritz RE (2011) Molecular technologies open new clinical genetic vistas. Sci Transl Med 3:22–25CrossRefGoogle Scholar
  38. Jans SM, de Jonge A, Henneman L, Cornel MC, Lagro-Janssen AL (2012) Attitudes of general practitioners and midwives towards ethnicity-based haemoglobinopathy-carrier screening. Eur J Hum Genet. doi:10.1038/ejhg.2012.72
  39. Johnson K, Posner SF, Biermann J, Cordero JF, Atrash HK, Parker CS, Boulet S, Curtis MG, Group CAPCW, Select Panel on Preconception C (2006) Recommendations to improve preconception health and health care-United States. A report of the CDC/ATSDR Preconception care work group and the select panel on preconception care. MMWR Recomm Rep 55:1–23PubMedGoogle Scholar
  40. Khoury MJ, McCabe LL, McCabe ER (2003) Population screening in the age of genomic medicine. N Engl J Med 348:50–8PubMedCrossRefGoogle Scholar
  41. Kolor K, Liu T, St Pierre J, Khoury MJ (2009) Health care provider and consumer awareness, perceptions, and use of direct-to-consumer personal genomic tests, United States, 2008. Genet Med 11:595PubMedCrossRefGoogle Scholar
  42. Lakeman P, Henneman L, Bezemer PD, Cornel MC, ten Kate LP (2006) Developing and optimizing a decisional instrument using self-reported ancestry for carrier screening in a multi-ethnic society. Genet Med 8:502–9PubMedCrossRefGoogle Scholar
  43. Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, ten Kate LP (2008) Three-month follow-up of Western and non-Western participants in a study on preconceptional ancestry-based carrier couple screening for cystic fibrosis and hemoglobinopathies in The Netherlands. Genet Med 10:820–30PubMedCrossRefGoogle Scholar
  44. Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, ten Kate LP (2009) Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation? Eur J Hum Genet 17:999–1009PubMedCrossRefGoogle Scholar
  45. Levenkron JC, Loader S, Rowley PT (1997) Carrier screening for cystic fibrosis: test acceptance and one year follow-up. Am J Med Genet 73:378–86PubMedCrossRefGoogle Scholar
  46. Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr, Rowley PT (1996) Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 59:234–47PubMedCentralPubMedGoogle Scholar
  47. McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M (2008) It is not in my world': an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 16:435–444PubMedCrossRefGoogle Scholar
  48. McQueen MJ (2002) Some ethical and design challenges of screening programs and screening tests. Clin Chim Acta 315:41–48PubMedCrossRefGoogle Scholar
  49. Mennie M, Campbell H, Liston WA, Brock DJ (1998) Attitudes of general practitioners to screening for cystic fibrosis. J Med Screen 5:11–5PubMedCrossRefGoogle Scholar
  50. Mennie ME, Compton ME, Gilfillan A, Liston WA, Pullen I, Whyte DA, Brock DJ (1993) Prenatal screening for cystic fibrosis: psychological effects on carriers and their partners. J Med Genet 30:543–8PubMedCrossRefGoogle Scholar
  51. Metcalfe SA (2012) Carrier screening in preconception consultation in primary care. J Community Genet 3:193–203PubMedCentralPubMedCrossRefGoogle Scholar
  52. Mitchell JJ, Capua A, Clow C, Scriver CR (1996) Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 59:793–8PubMedCentralPubMedGoogle Scholar
  53. Modra LJ, Massie RJ, Delatycki MB (2010) Ethical considerations in choosing a model for population-based cystic fibrosis carrier screening. Med J Aust 193:157–60PubMedGoogle Scholar
  54. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006–12Google Scholar
  55. Morgan MA, Driscoll DA, Mennuti MT, Schulkin J (2004) Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 6:450–5PubMedCrossRefGoogle Scholar
  56. Morgan MA, Driscoll DA, Zinberg S, Schulkin J, Mennuti MT (2005) Impact of self-reported familiarity with guidelines for cystic fibrosis carrier screening. Obstet Gynecol 105:1355–61PubMedCrossRefGoogle Scholar
  57. Morris JK (2004) Is cascade testing a sensible method of population screening? J Med Screen 11:57–58PubMedCrossRefGoogle Scholar
  58. Morris JK, Law MR, Wald NJ (2004) Is cascade testing a sensible method of screening a population for autosomal recessive disorders? Am J Med Genet A 128A:271–275PubMedCrossRefGoogle Scholar
  59. Ohata T, Tsuchiya A, Watanabe M, Sumida T, Takada F (2009) Physicians' opinion for 'new' genetic testing in Japan. J Hum Genet 54:203–208PubMedCrossRefGoogle Scholar
  60. Ormond KE, Mills PL, Lester LA, Ross LF (2003) Effect of family history on disclosure patterns of cystic fibrosis carrier status. Am J Med Genet C Semin Med Genet 119C:70–77PubMedCrossRefGoogle Scholar
  61. Payne Y, Williams M, Cheadle J, Stott NC, Rowlands M, Shickle D, West G, Meredith L, Goodchild M, Harper PS, Clarke A (1997) Carrier screening for cystic fibrosis in primary care: evaluation of a project in South Wales. The South Wales cystic fibrosis carrier screening research team. Clin Genet 51:153–163PubMedCrossRefGoogle Scholar
  62. Poppelaars FA, Henneman L, Ader HJ, Cornel MC, Hermens RP, van der Wal G, ten Kate LP (2003a) How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population. Community Genet 6:157–165PubMedCrossRefGoogle Scholar
  63. Poppelaars FA, van der Wal G, Braspenning JC, Cornel MC, Henneman L, Langendam MW, ten Kate LP (2003b) Possibilities and barriers in the implementation of a preconceptional screening programme for cystic fibrosis carriers: a focus group study. Public Health 117:396–403PubMedCrossRefGoogle Scholar
  64. Poppelaars FA, Ader HJ, Cornel MC, Henneman L, Hermens RP, van der Wal G, ten Kate LP (2004) Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening. J Genet Couns 13:31–44PubMedCrossRefGoogle Scholar
  65. Powell KP, Cogswell WA, Christianson CA, Dave G, Verma A, Eubanks S, Henrich VC (2012) Primary care physicians' awareness, experience and opinions of direct-to-consumer genetic testing. J Genet Couns 21:113–126PubMedCrossRefGoogle Scholar
  66. Qureshi N, Armstrong S, Modell B (2006) GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. Fam Pract 23:106–110PubMedCrossRefGoogle Scholar
  67. Radhakrishnan M, van Gool K, Hall J, Delatycki M, Massie J (2008) Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 85:133–147PubMedCrossRefGoogle Scholar
  68. Raeburn JA (1994) Screening for carriers of cystic fibrosis. Screening before pregnancy is needed. BMJ 309:1428–1429PubMedCrossRefGoogle Scholar
  69. Ready K, Haque IS, Srinivasan BS, Marshall JR (2012) Knowledge and attitudes regarding expanded genetic carrier screening among women's healthcare providers. Fertil Steril 97:407–413PubMedCrossRefGoogle Scholar
  70. Riskin-Mashiah S, Auslander R (2007) Preconception care–when and what: the attitude of Israeli gynaecologists to preconception counseling. Arch Gynecol Obstet 275:367–371PubMedCrossRefGoogle Scholar
  71. Roberts T, Schwarz MJ, Kerr-Liddell R, Hinks JL, Super M (2003) Cascade carrier-testing in cystic fibrosis. Paediatr Respir Rev 4:293–298PubMedCrossRefGoogle Scholar
  72. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N et al (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–1065PubMedCrossRefGoogle Scholar
  73. Ross LF (2006) Heterozygote carrier testing in high schools abroad: what are the lessons for the U.S.? J Law Med Ethics 34:753–764PubMedCrossRefGoogle Scholar
  74. Rowley PT, Loader S, Levenkron JC, Phelps CE (1993) Cystic fibrosis carrier screening: knowledge and attitudes of prenatal care providers. Am J Prev Med 9:261–266PubMedGoogle Scholar
  75. Shickle D, May A (1989) Knowledge and perceptions of haemoglobinopathy carrier screening among general practitioners in Cardiff. J Med Genet 26:109–112PubMedCrossRefGoogle Scholar
  76. Watson EK, Marchant J, Bush A, Williamson B (1992) Attitudes towards prenatal diagnosis and carrier screening for cystic fibrosis among the parents of patients in a paediatric cystic fibrosis clinic. J Med Genet 29:490–491PubMedGoogle Scholar
  77. Watson EK, Williamson R, Chapple J (1991) Attitudes to carrier screening for cystic fibrosis: a survey of health care professionals, relatives of sufferers and other members of the public. Br J Gen Pract 41:237–240PubMedCentralPubMedGoogle Scholar
  78. Weinreich SS, de Lange-de Klerk ES, Rijmen F, Cornel MC, de Kinderen M, Plass AM (2009) Raising awareness of carrier testing for hereditary haemoglobinopathies in high-risk ethnic groups in The Netherlands: a pilot study among the general public and primary care providers. BMC Publ Health 9:338. doi:10.1186/1471-2458-9-338 CrossRefGoogle Scholar
  79. Verweij M (2008) Preconceptional CF screening and the problem of medicalisation. In: Lakeman P (ed) Preconceptional carrier couple screening for cystic fibrosis and hemoglobinopathies, An ancestry-based offer in a multi-ethnic society. Gildeprint drukkerijen en B.V., Enschede, Amsterdam, pp 265–271Google Scholar
  80. Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. Geneva: World Health Organisation. Public Health Papers No.34 (No.34). Available at: http://apps.who.int/iris/bitstream/10665/37650/1/WHOPHP34.pdf
  81. Witt DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, Holtzman J, Kornfeld S, Lee R, Nemzer L, Palmer R (1996) Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 58:823–35PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Center for Medical Genetics GhentUniversity Hospital GhentGhentBelgium
  2. 2.Center for Biomedical Ethics and LawUniversity of LeuvenLeuvenBelgium

Personalised recommendations